Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To verify the superiority of celecoxib (YM177) 200 mg bid to placebo in treatment of patients
with low back pain as well as non-inferiority to loxoprofen sodium 60 mg tid.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.